$MOH (+0,21 %) stock is down nearly -25% from YTD highs, but Q2 results show stabilizing medical expense ratios, assuaging investor fears.

Its attractive valuation, cost control strategies, and growth outlook make it a potential buy for investors looking for long-term upside. Anyone bullish on this stock?🤔